FDA's CBD Docket Comments: Harm Reduction To Churches, 'More Humane' Medication To 'Source Of Confusion'
Executive Summary
Consumers' submissions, many with anonymous attribution, account for most of the 776 comments FDA has received to its "Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds" docket. Few provide data or other information FDA asks for and some organizations' comments align with consumers by focusing on sentiment and appreciation.
You may also be interested in...
US Wellness Market In 2019: Farm Bill Made Cultivating Cannabidiol Policy FDA's Main Course In Supplements
As HBW Insight looks back on notable US wellness market developments and events for the previous 12 months, we find that news in the CBD space from the FDA and the industry dominated the sector throughout 2019.
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.
MLM Group Not Buying FTC Executive’s Concerns About Its Income Disclosure Guidance
FTC Division of Marketing Practices assistant director concerned direct selling self-regulation group’s guidance “will encourage deceptive conduct and facilitate deceptive earnings claims.” DSA president says the concerns might reflect the thinking of agency’s staff more than the intent of the agency’s regulations.